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Abstract: Thiolated chitosan has high transfection and mucoadhesive properties. 
We investigated the potential of two recently synthesized polymers: NAC-C (N-acetyl 
cysteine-chitosan) and NAP-C (N-acetyl penicillamine-chitosan) in anticancer drug deliv-
ery targeting epidermal growth factor receptor (EGFR). Doxorubicin (DOX) and antisense 
oligonucleotide (ASOND)-loaded polymer nanoparticles were prepared in water by a gela-
tion process. Particle characterization, drug loading, and drug release were evaluated. To 
verify drug delivery efficiency in vitro experiments on a breast cancer cell line (T47D) were 
performed. EGFR gene and protein expression was analyzed by real time quantitative poly-
merase chain reaction and Western blotting, respectively. A loading percentage of 63% ± 5% 
for ASOND and 70% ± 5% for DOX was achieved. Drug release data after 15 hours showed 
that ASOND and DOX were completely released from chitosan-based particles while a 
lower and more sustained release of only 22% ± 8% was measured for thiolated particles. 
In a cytosol simulated release medium/reducing environment, such as found intracellularly, 
polymer-based nanoparticles dissociated, liberating approximately 50% of both active sub-
stances within 7 hours. ASOND-loaded polymer nanoparticles had higher stability and high 
mucoadhesive properties. The ASOND-loaded thiolated particles significantly suppressed 
EGFR gene expression in T47D cells compared with ASOND-loaded chitosan particles and 
downregulated EGFR protein expression in cells. This study could facilitate future investiga-
tions into the functionality of NAP-C and NAC-C polymers as an efficient ASOND delivery 
system in vitro and in vivo.
Keywords: thiolated chitosan, nanoparticles, doxorubicin, antisense oligonucleotide, epidermal 
growth factor receptor, T47D breast cancer cells, controlled release
Introduction
As our understanding of the biological systems at molecular level increases, most of the 
biological expressions including onset of pathogenesis can be attributed more precisely 
to molecular dysfunctions.1 The promise of using antisense oligonucleotide (ASOND) 
to control gene function in diseased cells was first recognized over 20 years ago,2 but 
the major challenge in translating promise into clinical utility has been the lack of a 
method in delivering ASOND-based drugs to cells while avoiding the breakdown of 
these oligonucleotides through formulation or along the delivery routes. Thus, even 
though in vitro laboratory studies have been promising, the pace of developing this 
new class of drugs has been slow because of the difficulties mainly present in DNA/
RNA delivery to the cells.3 ASONDs are able to downregulate or specifically turn off 
individual genes and have therefore received much attention in gene therapy considering International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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their relative ease of synthesis and use.4 In the fight against 
cancer, ASOND-based drugs that block cancer genes from 
producing malicious proteins have the potential to become 
a powerful new weapon to complement drugs that function 
in other different ways.
ASOND is quite effective in decreasing gene   expression 
and protein production, a process known as gene knock 
down.5 Polymers and lipoplexes are two main vehicles with 
high potential to be used in ASOND drug delivery. Although 
7.1% of the gene therapy clinical trials by March 2010 were 
based on lipoplexes,6 several problems continue to limit their 
application as drug products for human use. For instance, 
the formation of lipoplexes involves complex interactions 
between the lipid molecules, in addition to those with nucleic 
acids. Additionally, the ability to control the size and mor-
phology of lipoplexes is rather limited, with resultant insta-
bility problems over time.7 Furthermore, toxicity associated 
with the use of lipoplexes in terms of immune stimulation 
of the host can also limit in vivo   application. The toxicity of 
lipoplexes is closely associated with the administered dose 
and it may in part result from their large size and the high 
positive surface charge.8,9 According to these limitations cat-
ionic polymers are interesting alternatives to cationic lipids. 
Furthermore the self-assembly of polymer nanoparticles 
does not involve interactions of the polycation molecules 
with each other, resulting in better control of their physical 
properties compared with lipoplexes. The chemical structures 
of various polymers contain repeated units that can be easily 
manipulated by chemical modification to improve the physi-
cal and biological properties of the resultant polyplexes, and 
consequently enhance their transfection   efficiency.10 Among 
the different properties studied in relation to nanoparticles, 
particle size and stability are the most critical issues that can 
affect the drug delivery process. According to this knowl-
edge, a careful choice of nanoparticle formulation method 
is necessary in preparing particles which are loaded with 
different substances.
Epidermal growth factor receptor (EGFR) is a trans-
membrane receptor whose overexpression in breast cancer 
predicts poor prognosis and is inversely correlated with 
expression of estrogen receptor.11 T47D cells belong to a 
moderately malignant breast cancer cell line which is placed 
somewhere in between MCF7 and BT474 breast cancer cell 
lines according to EGFR expression level.12 The inhibition 
of EGFR expression in all three cell lines has been shown 
to significantly inhibit cancer growth; thus any of these cells 
could be chosen to assess the potential of EGFR inhibition 
using an anticancer formulation.
Owing to its proven cytocompatibility, biodegradability, 
low toxicity, and high cationic potential, chitosan is a suitable 
candidate as a drug carrier.13 Thiolated chitosan has a high 
level of cohesive-, mucoadhesive-, enzyme inhibitory-, and 
permeation-enhancing properties,14 In order to investigate and 
evaluate the various properties of two recently   synthesized 
thiolated chitosan polymers, N-acetyl cysteine-chitosan 
(NAC-C) and N-acetyl penicillamine-chitosan (NAP-C), 
in anticancer drug delivery, these agents were formulated 
as nanoparticles loaded with ASOND and doxorubicin 
(DOX), which are known anticancer agents. This study 
further endeavored to establish the potential efficiency of 
these particles in an in vitro cancer model cell line known 
as T47D (human breast epithelial tumor cells) and evaluate 
the results.
Materials and methods
Preparation of thiolated chitosan
To prepare low-molecular-weight chitosan (LMWC), 500 mg 
of chitosan (medium molecular weight: 400 kDa; deacetyla-
tion degree 84.7%; Fluka Germany) was dissolved in acetic 
acid (6% [v/v]). Sodium nitrite (NaNO2, 20 mg) dissolved 
in 2.5 mL demineralized water was added to the solution of 
polymer. The mixture was incubated for 1 hour under continu-
ous stirring. Sodium hydroxide (4 M) was added to the mix-
ture leading to LMWC precipitation at pH 9. The precipitate 
was filtered and washed with cold acetone. The residue was 
resolubilized in 3.5 mL of 0.1 M acetic acid and exhaustively 
dialyzed against demineralized water using a dialysis tube 
(MW cut-off 12 kDa) followed by lyophilization at –30°C 
and a pressure down to 0.01 mbar. The molecular weight of 
the hydrolyzed chitosan was determined by dynamic light 
scattering using a nanosizer instrument (Malvern Zetasizer 
laser, Malvern Instruments, UK).
Two previously synthesized and characterized thiolated 
chitosans were prepared.14 Due to its significant effect on 
formulation size, conformation, and drug delivery LMWC 
(15 kDa) was used for thiolated chitosan preparation.15 
Briefly, 300 mg EDAC (1-ethyl-3-(3-dimethyl-aminopropyl) 
was added to 500 mg LMWC dissolved in 50 mL distilled 
water containing 2 mL HCl (1 N) and agitated for complete 
dissolution of EDAC. NAC or NAP (500 mg) was added to 
the mixture. The pH value of the preparations was adjusted 
to 5 and the mixtures were left at room temperature for 
3 hours under continuous stirring and capped with nitrogen 
gas-filled balloons to prevent oxidation of thiol groups during 
the synthesis process. Other samples serving as controls were 
prepared by the same method excluding EDAC. To isolate International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the conjugated polymer and eliminate the unbound NAC or 
NAP, the mixtures were dialyzed for 3 consecutive days at 
10°C in the dark using a dialysis tube (MW cut off 12 kDa) 
as follows: first against 1.4 mM lactic acid, and then twice 
against the same medium but containing 1% NaCl to reduce 
ionic interaction between the cationic polymer and the anionic 
sulfhydryl groups, followed by dialysis against 1.4 mM lactic 
acid, and finally against 0.6 mM lactic acid to adjust the pH 
to 4. After 3 days the samples were lyophilized at –30°C and 
stored at 4°C for further use.
cell toxicity assays
A stable formulation should have a low cell toxicity with 
minimum effect on cell growth or viability. Roswell Park 
Memorial Institute culture medium (RPMI), containing salts, 
amino acids, and vitamins, was used as the T47D breast can-
cer cell medium in these experiments. RPMI 1640 (Gibco) 
culture medium supplemented with 10% fetal bovine serum 
(FBS) and 100 U/mL penicillin, 100 µg/mL streptomycin, 
2 mmol/L L-glutamine, and 1 mmol/L sodium pyruvate 
(Invitrogen) was prepared under sterile conditions. The 
T47D culture medium was kept at 4°C and warmed to 37°C 
before use. A breast cancer wild type cell line, T47D, was 
obtained from the American Type Culture Collection. This 
differentiated epithelial cell line contains both estrogen and 
progesterone receptors with a medium level of EGFR expres-
sion compared with other breast cancer cell lines.
Stocks of synthesized polymers (NAC-C, NAP-C) and 
control (LMWC) with predetermined concentrations of 0.25, 
0.5, 1.0, and 2.0 mg/mL in acetate buffer (5 mM; pH 5.5) 
were prepared. These concentrations were obtained after 
the study of particle conformation and stability. In brief, 
10 mg/mL stock concentrations of synthesized polymers 
(NAC-C, NAP-C) and control (LMWC) were used to prepare 
0.25, 0.5, 1.0, and 2.0 mg/mL solutions in a mixture contain-
ing dextrose (1%) and sodium sulfate (5 mM) at a ratio of 3:1. 
The preparations were then filtered using 0.22-µm filters.
T47D cells were thawed and counted using the direct 
method of Trypan blue dye exclusion.16,17 The cells were 
plated at 10,000 cell per well in a 96-well culture plate using 
RPMI supplemented only with 10% FBS. The plates were left 
at 37°C inside a 5% CO2 incubator. The medium of the wells 
containing cells with 80% confluence was replaced by 100 µL 
of medium containing 12 µL of each sample’s concentrate 
preparation mixed with 88 µL of free RPMI. The plates were 
kept inside the incubator at 37°C for 24 hours. The culture 
medium was then replaced with RPMI containing both FBS 
and antibiotic. The optical density (OD) of each well was   
measured by a solution composed of a novel tetrazolium 
compound [3-(4,5-  dimethylthiazol-2-yl)-5-  (3-carboxymet
hoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; 
MTS] and an electron coupling reagent (phenazine metho-
sulfate). In this assay, known as MTS assay, 20 µL of the 
ready to use solution is added to each well and the plates 
are placed at 37°C for 2 hours followed by the measurement 
of the absorption using a plate reader at 490 nm wavelength 
following promega protocol.18 The experiments were repeated 
three times and the data were collected each time from four 
wells to compare with control data (FBS-free RPMI).
Preparation of drug-loaded nanoparticles  
and investigation of physical and toxicological 
properties
A 2 mg/mL stock solution of DOX (Sigma D1515) in normal 
saline was mixed with RPMI to prepare a 2.5*10–7 M solution. 
ASOND stock (2.5 µL of 100 µM) was mixed with 37.5 µL 
dextrose (1%) and 10 µL sodium acetate buffer to a volume 
of 50 µL (ASOND sequence; 5′-CCGTGGTCATGCTCC-3′, 
complementary to positions 3811–3825 of the human EGFR 
cDNA, which contains the opal translation termination 
codon at residues 3817–3819). To prepare drug-loaded 
nanoparticles a concentration of 0.5 mg/mL polymer in 
sodium acetate buffer was prepared. Sodium sulfate (Na2SO4, 
5 µL of 5 mM) was added to ASOND (12 µL) and DOX 
(180 µL) stock solutions and 2.5 µL of the polymer stock 
solution was added to each tube. The spontaneously formed 
nanoparticles were vortexed for 50 seconds.19   Drug-loaded 
nanoparticles were recovered by centrifugation at 19,000 
rpm for 30–45 minutes and washed three times with distilled 
water to obtain the final pellet, which was lyophilized and 
kept at 4ºC for future experiments.
To study the stability of the particles, nanoparticles were 
exposed to acidic and basic media (0.1 N HCl and 0.01 N 
NaOH). Nanoparticle formulations were stored in glass tubes 
covered with aluminum foil and left for 24 hours at two tem-
peratures: 30 ± 2°C and 4 ± 2°C. A vacuum chamber was used 
to remove the residual water. Different particle formulations 
were sputter-coated with a gold layer (sputter coater AGAR 
B7340, Standard, UK) and viewed with a scanning electron 
microscope (SEM; Philips XL30 Scanning microscope, 
Philips, the Netherlands) to assess morphological changes.
To assess the cell toxicity levels of the active sub-
stances and nanoparticle formulations, T47D cells were 
plated at 10,000 cells/well in 96-well plates. After reaching 
80% confluence, the cells were brought into contact with International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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100 µL of FBS-free RPMI containing above-mentioned 
concentrations of DOX, ASOND, and 0.5 mg/mL of 
nanoparticle   formulations (NAC-C, NAP-C and LMWC, 
ASOND + NAC-C, ASOND + NAP-C, ASOND + LMWC, 
DOX + NAC-C, DOX + NAP-C and DOX + LMWC) for 
24 hours at 37°C. FBS-free and FBS-enriched RPMI were 
chosen as controls to exclude any chance of FBS interaction 
with cationic   polymers. T47D cell survival was assessed by 
applying a standard MTS assay following the same procedure 
as explained in Cell toxicity assays section. The experiments 
were repeated three times and the data were collected each 
time from four wells and compared with control data.
Drug-loading and drug-release studies
The release of DOX and ASOND from nanospheres was 
monitored in the presence of 20 mM sodium phosphate buf-
fer pH 7. Nanoparticle solutions were filled into a 12 kDa 
MW cut-off dialysis tube (Sigma-Aldrich, St. Louis, MO) 
and dialyzed against 1 × PBS (phosphate buffer saline) for 
15 hours at 37°C. Dissolution medium (1 mL) was taken at 
different time points for analysis of drug concentration in 
solution. The amount was replaced each time by fresh PBS 
to prevent drug saturation. The oligonucleotide concentration 
in the medium was determined by comparing the UV absor-
bance values (λ = 260 nm) before and after release.20
The concentration of the DOX released into the medium 
was determined using a UV-spectrophotometer (UV spectro-
photometer 1201, Shimadzu Co. Japan) at 488 nm.21
To study the effects of a reducing environment on drug 
release from these particles, a simulated environment similar 
to that of cytosol was created according to Carlisle et al22 by 
the addition of 0.01% threo-1,4-dimercapto-2,3-butandiol 
(DTT) as a reducing agent to PBS medium replacing PBS in 
the above experiment. The release data in this medium were 
obtained and compared with PBS medium data.
Drug content and loading efficiency of nanoparticles were 
calculated by the following formulae:
Drug contents =   [(drug weight in the nanoparticles)/
(weight of nanoparticles)] × 100
Loading efficiency =   [(Residual drug in the nanopar-
ticle)/(initial feeding amount of 
drug)] × 100
rT-Pcr and sYBer green real time Pcr
T47D cells were seeded in FBS-free RPMI in a 96-well cul-
ture plate. Twenty-four hours later the medium over the cells 
was replaced with 100 µL FBS free RPMI (control), poly-
meric nanoparticles ± ASOND and DOX (ASOND + NAC-C, 
NAC-C, DOX + NAC-C, NAP-C, ASOND + NAP-C, 
Dox + NAP-C, chitosan, ASOND + chitosan, DOX + chitosan), 
free ASOND and free DOX at concentrations previously 
mentioned (section Preparation of drug-loaded nanoparticles) 
All preparations were diluted in FBS-free RPMI to a final 
volume of 100 µL. The plates were incubated for 24 hours at 
37ºC and the culture medium was replaced by RPMI medium 
containing both FBS and antibiotic. Twenty-four hours later, 
the culture medium over the cells was emptied and 200 µL 
of TRI reagent was added to each well. The plates were put 
on a shaker for 5 minutes and the content of each well was 
then emptied into a sterile RNase/DNase-free microtube. 
Chloroform (120 µL) was added to each microtube. The 
tubes were vortexed for 15 seconds and incubated at room 
temperature for 10 minutes.
The samples were centrifuged at 11,000 rpm to separate 
the different phases. Three phases were separated with the 
upper phase containing RNA. This phase was transferred 
to a clean microtube and 300 µL of isopropanol was added 
to the tubes and mixed for 10 minutes at room temperature. 
The samples were then centrifuged at 4°C at 11,000 rpm for 
10 minutes. The above solution was emptied and 750 µL 
ethanol 75% (7.5 mL Merck ethanol and 2.5 mL RNase-free 
diethylpyrocarbonate [DEPC] water) was added to the white 
precipitate of RNA and mixed with a vortex instrument to 
wash the RNA residual. These samples were then centrifuged 
at 4°C and 11,000 rpm for 7 minutes. The above solution was 
emptied and the RNA precipitate was left to dry at room tem-
perature. The concentration and quality of the RNA samples 
were investigated using a spectrophotometer. The precipitated 
RNA was diluted in 50 µL of DEPC water and transferred into 
a fresh microtube. The measured OD was incorporated into 
the following formula: [RNA] (µg/mL) = A260 × Dilution 
Coefficient × 40.
The purity of RNA was determined by calculating OD 
260/280 ratio which was measured as ∼1.9, indicating the 
absence of protein or phenol contaminants. The RNA samples 
were stored at –20°C.
RevertAid™ First Strand cDNA Synthesis kit was used 
to make cDNA from RNA extracts according to the protocol 
provided by manufacturer.23 The product of RT was trans-
ferred to –20°C for later use in real time QPCR (quantitative 
polymerase chain reaction).
Specific EGFR primers were used to amplify the EGFR 
sequence in cDNA. EGFR primers [(forward) I (18-mer): 
5′-CAACATCTCCGAAAGCCA, and (reverse) II (19-mer): 
5′-CGGAACTTTGGGCGACTAT] and β-actin primers 
[(forward), 5′-GTCCTGTGGCATCCATCCACGAAACT International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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and (reverse), 5′-TACTTGCGCTCAGGAGGAGCAA] were 
provided by TIB MOLBIOL Company.
SYBR green real time PCR was performed using Bio-Rad 
CFX384 C1000 and analyzed using Bio-Rad CFX manager 
2.0 with reagents from the SYBR green PCR kit (QIAgen). 
After the addition of all components for each sample into the 
PCR 384 well plate with each well containing a final volume 
of 10 µL, the samples were transferred to a thermal cycler 
and PCR was started as follows: predenaturation at 94°C 
(5 minutes; one cycle) followed by 35 cycles of denatur-
ation at 94°C (30 seconds), annealing at 57°C (30 seconds), 
extension at 72°C (45 seconds), and a final extension at 72°C 
(8 minutes; one cycle), followed by a melting curve. All Ct 
(cycle threshold) values were collected at the exponential 
phase of the real time QPCR.
evaluation of egFr protein expression
T47D cells were seeded in FBS containing RPMI in six-
well culture plates. Twenty-four hours later the medium 
over the cells was emptied and PBS was used to wash 
the cells. The same groups (section RT-PCR and SYBER 
Green real time PCR) were prepared with appropriate 
polymer and drug concentrations in a volume of 1 mL 
FBS-free RPMI for each well. The plates were incubated 
for 24 hours at 37°C and the culture medium was replaced 
with RPMI medium containing both FBS and antibiotic. 
Forty-eight hours later, the culture medium over the cells 
was emptied and the treated and untreated T47D cells in 
six-well plates were washed with PBS and lysed in 120 µL 
RIPA buffer (1 mM EDTA, 1% Triton X-100, 0.1% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate, 140 mM 
NaCl) supplemented with protease inhibitor on ice. The 
protein concentration was measured by Bradford assay 
in all the samples. Loading buffer (20 µL) was added to 
every 50 µg of cell protein and run at 100 V for 70 minutes. 
Proteins were transferred to a nitrocellulose membrane and 
incubated with EGFR antibody (1:1000) overnight. The 
next day the membranes were washed and incubated with 
the secondary antibody for 2 hours at room temperature. 
Expression of EGFR (170 kDa) was detected by West Pico 
Chemiluminescent Substrate (SuperSignal, Thermo Scien-
tific), photographed, and analyzed with genetool software 
(version 3.08, SynGene).
For immunocytochemical examination of T47D cells, 
cells were cultured on round glass cover-slips and treated as 
previously described. After the treatment cells were washed 
with PBS and fixed by acetone (100%) for 10 minutes 
at room temperature, washed and rehydrated with PBS. 
Hydrogen peroxidase activity was blocked by hydrogen 
peroxide (1%) in PBS for 30 minutes and the slides were 
washed in PBS three times for 5 minutes each and incubated 
for 1 hour with 1% primary antibody to EGFR (rabbit, 
Santa Cruz SC-03) in PBS containing 1% bovine serum 
albumin (BSA) for 1 hour at room temperature, washed in 
PBS three times and incubated with 1% secondary antibody 
Goat AntiRabbit HRP (Dako, po448) in PBS containing 
1% BSA for 1 hour at room temperature and again washed 
in PBS three times to remove the unbound antibodies. The 
signal was amplified by 1% of a third antibody, rabbit Anti 
Goat (Dako, po449) in PBS containing 1% BSA. The slides 
were washed in PBS and Dako AEC + High Sensitivity 
Substrate Chromogen (k3469) was used in all stainings to 
visualize protein bond antibody. The nuclei were visualized 
by hematoxylin counterstaining blue staining of the cell 
nuclei. The slides were washed in water and covered by 
glass cover-slips and photographed at 40× resolution using 
a light microscope and camera.
statistical data analysis
Statistical analysis was performed using GraphPad Prism 
version 5.00 for Windows (GraphPad Software, San 
Diego CA). ANOVA was used with Tukey test to compare 
the data groups with control.
Results and discussion
synthesis of chitosan conjugates
LMWC with a molecular weight of 15 kDa and 100% 
solubility at pH 7 was prepared. NAC and NAP attached 
covalently to the primary amino groups of chitosan via 
formation of amino bonds. The final structures are shown 
in Figure 1. EDAC (carbodiimide) activated the carboxylic 
acid moieties of NAC and NAP. LMWC was treated by the 
same procedure omitting EDAC during the coupling reaction 
and used as control. The lyophilized NAC-C and NAP-C 
appeared as white, odorless powders of fibrous structure that 
swelled easily at pH , 8 and formed a transparent gel of high 
viscosity. The lyophilized conjugates were stored at 4°C. The 
characterization of these polymers has been already reported 
in our previous study.14 The amount of thiol groups grafted on 
chitosan was determined via iodometric titration at pH 1–2 
(1 mM iodine; indicator: starch). It was estimated that the 
highest amount of grafted thiol groups was obtained by the 
addition of 300 mg EDAC at pH 5, with immobilization of 
300 µmol of thiol groups per gram chitosan. In the following 
experiments only polymers obtained from this optimum 
condition were used.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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cell toxicity assay
For toxicological evaluation, different concentrations of poly-
mers were tested on T47D cells and the level of cell prolifera-
tion was compared with FBS-free RPMI as control by MTS 
assay. The results indicate that all polymers have a low but 
significant degree of toxicity compared with FBS-free RPMI. 
Thiolated chitosan polymers did not show a higher level of 
toxicity than LMWC (Figure 2). The lower the   concentration 
of polymers the more similar are the measured effect they 
have on the wells containing T47D cells, enabling us to 
prevent variation in measurements. There was a significant 
difference in cell proliferation with polymer concentrations 
compared with FBS-free RPMI. According to the results 
achieved in cell toxicity studies, the 0.5 mg/mL concentration 
of the polymers was chosen to perform future experiments. 
Polymers in this concentration formed the desired spherical 
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nanoparticles with a diameter of 150–300 nm and accord-
ing to the results obtained later on, were able to capture and 
carry active substances to the desired site. ANOVA was used 
with Tukey test to compare the data groups to control. All 
the data groups showed a significant difference compared to 
control (P , 0.0001).
Preparation of nanoparticles and nanoparticle 
characterization
Nanoparticles containing DOX and ASOND were prepared 
following the procedure explained in section Preparation of 
drug-loaded nanoparticles. The drug-loaded nanoparticles 
were centrifuged at high speed, the supernatant was emptied, 
and the remaining nanoparticles were lyophilized. Polymer 
nanoparticles without any drug were also prepared to make 
a comparison with those containing the active substances. 
The SEM micrograph from four different formulations are 
shown in Figure 3 (A–D); 80%–90% of the particles had a 
size range of 200–300 nm with a spherical shape.
These nanoparticles were dispersed in phosphate buffer 
(pH 7.4) and analyzed based on their surface charge and size 
with a sharp peak at the indicated points (Table 1), indicat-
ing a 55 ± 5% particle size distribution frequency (data not 
shown). Thiolated chitosan particles had a higher zeta poten-
tial than chitosan but zeta potential decreased significantly for 
nanoparticles containing ASOND. The lower zeta potential 
obtained for ASOND-containing particles is probably due 
to the negative charge of the active substance.24
In particles containing DOX the zeta potential of the 
particles slightly increased due to the cationic nature of this 
substance.25 The particle size for all formulations remained 
in the range 200–230 nm. The size range of these particles is 
comparable to the particle sizes obtained by other groups.26
Cell toxicity assay conducted according to MTS where 
active substances and formulated nanoparticles were used 
demonstrated that DOX in any form (free/nanoparticle) 
applied to cells was toxic and significantly decreased cell 
survival in comparison with both controls (RPMI + 10% 
FBS and FBS-free RPMI) and other treatments (Figure 4). 
Thus the cells were not resistant to this compound. Thiolated 
nanoparticles containing ASOND showed lower cytotoxic 
effects than free ASOND thus signifying a lower toxicity 
of ASOND in nanparticle formulation. NAC-C and NAP-C 
did not show higher cell toxicity levels than chitosan and 
FBS-free RPMI (negative control.) All the treatments 
showed a significant decrease in cell survival compared with 
RPMI + 10% FBS (positive control). FBS-enriched RPMI 
medium had the highest growth-inducing effect on cells and 
DOX-containing medium showed the highest inhibitory 
effect on cell proliferation.
Drug-loading and drug-release studies
The thiolated nanoparticles had a loading efficiency of 63% 
for ASOND and 70% for DOX. LMWC nanoparticles con-
taining ASOND or DOX had a 50%–60% loading efficiency. 
ASOND had a negative charge, probably forming a stronger 
binding force to the positively charged polymers like thio-
lated chitosan. Entrapment of DOX, a cationic and hydro-
philic molecule, into nanoparticles formed by ionic gelation 
of the positively charged polysaccharides, chitosan/thiolated 
chitosan, was achieved successfully probably due to the 
addition of Na2SO4 directly to this substance as it contributes 
to the decreasing water solubility of DOX.27 In examining 
thiolated chitosan particles exposed to either acidic or basic 
media (0.1 N HCl and 0.01 N NaOH) no particular change 
was observed according to SEM graphs, demonstrating the 
stability in both media. The release of drug from particles was 
examined in PBS (pH 7.4). In a second experiment the release 
studies were performed under reducing conditions achieved 
by 0.01% DTT, simulating intracellular redox conditions 
of cytosol as described previously by Carlisle et al.28 There 
was a controlled release pattern during 15 hours for all the 
AB CD
250 nm
Figure 3 representative seM micrograph of nanoparticles formulated via sulfate gelation with Na2sO4. (A) chitosan nanoparticles, (B) thiolated chitosan (NAP-c) 
nanoparticles, (C) DOX-NAc-c nanoparticles, (D) AsOND-NAc-c nanoparticles demonstrate a spherical, uniform shape with a particle size of 150–300 nm.
Abbreviations:  DOX,  doxorubicin;  NAc-c,  N-acetyl  cysteine-chitosan;  NAP-c,  N-acetyl  penicillamine-chitosan;  AsOND,  antisense  oligonucleotide;  seM,  scanning 
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particles (Figure 5A and B). Chitosan nanoparticles tended to 
have a faster rate of release probably because nanoparticles 
are less stable due to the lack of disulfide bonds compared 
with thiolated chitosan. Within 15 hours, ASOND and DOX 
were completely released from chitosan-based particles 
while only about 22% of drug was released from thiolated 
chitosan-based particles. These nanoparticles dissociated, 
liberating approximately 50% of both compounds within 
7 hours. Thiolated chitosan nanoparticles were very stable, 
having formed inter-/intra-molecular disulfide bonds and 
decreasing drug release compared with chitosan particles. 
A reducing agent like DTT breaks up such bonds helping 
the release of drug from thiolated nanoparticles, a process 
similar to what happens inside a cell (Figure 5 A and B). The 
simulated medium did not affect drug release from chitosan 
nanoparticles and the data were not included in the graph.
Analysis of egFr gene expression  
in T47D cells
T47D cells were brought into contact with different formu-
lations. RNA was extracted from the cells and DNA was 
synthesized from the sequence. The DNA obtained from the 
reaction was amplified using specific primers against EGFR 
and β-actin by RT QPCR. The data were collected at the 
exponential phase of the reaction. The EGFR Ct value was 
normalized to β-actin (house keeping gene) and the relative 
expression for each sample was measured.   Figure 6 shows the 
percentage knock down of EGFR in different treatments com-
pared with FBS-free RPMI-treated cells (0% knock down.) 
Table 1 The surface charge and size of different nanoparticle 
formulations was measured by a zeta sizer instrument in phos-
phate buffer
Nanoparticle  
formulations (N = 3)
Zeta potential  
(mV)
Nano particle   
size (nm)
NAc-c-AsOND 14 ± 3 224 ± 5
NAP-c-AsOND 16 ± 2 201 ± 10
chitosan-AsOND 12 ± 2 264 ± 5
NAP-c-DOX 20 ± 3 275 ± 5
NAc-c-DOX 20 ± 3 326 ± 5
chitosan-DOX 21 ± 2 227 ± 5
NAc-c 23 ± 3 214 ± 10
NAP-c 22 ± 4 188 ± 5
chitosan 18 ± 2 224 ± 5
Abbreviations: AsOND, antisense oligonucleotide; DOX, doxorubicin; NAc-c, 
N-acetyl cysteine-chitosan; NAP-c, N-acetyl penicillamine-chitosan.
Notes: Data represent the mean of three replicates in two separate experiments 
(mean ± sD).
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Figure 4 MTs assay measured the effect of polymer nanoparticles (0.5 mg/mL) containing AsOND and DOX (25 × 10-7 M) on T47D cancer cell proliferation 24 hours after 
treatment. The data are mean ± sD of three separate experiments in four wells. In ANOVA tests all the data were compared with controls (rPMI + 10% FBs- and FBs-free rPMI).
Notes: *Significantly different from FBS-free RPMI; #rPMI + 10% FBS is significantly different from all the other treatments (P < 0.0001).
Abbreviations: AsOND, antisense oligonucleotide; DOX, doxorubicin; MTs, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetrazolium, 
NAc-c, N-acetyl cysteine-chitosan; NAP-c, N-acetyl penicillamine-chitosan; LMWc, low-molecular-weight chitosan; rPMI, roswell Park Memorial Institute medium; FBs, 
fetal bovine serum; sD, standard deviation.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 5 Percentage release of AsOND and doxorubicin from 5 mg of drug-loaded nanoparticles during 15 hours in PBs and cytosol simulated medium using DTT. 
(A) Percentage release of AsOND, (B) Percentage release of doxorubicin. The release data are mean ± sD for each formulation at different time points indicated (n = 4).
Abbreviations:  AsOND,  antisense  oligonucleotide;  DOX,  doxorubicin;  NAc-c,  N-acetyl  cysteine-chitosan;  NAP-c,  N-acetyl  penicillamine-chitosan;  LMWc,  low-
molecular-weight chitosan; rPMI, roswell Park Memorial Institute medium; FBs, fetal bovine serum; PBs, phosphate buffered saline; DTT, threo-1,4-dimercapto-2,3-
butandiol; sD, standard deviation.
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Figure 6 real-time Pcr analysis of egFr gene expression in T47D cells subjected to different treatments. The results were normalized to beta-actin gene expression and the relative 
expression of egFr was presented as percent knock down of egFr. FBs-free rPMI treatment was chosen as control, which presented no knock down of egFr and all the other cell 
treatments were compared with this control. All data are presented as percent knock down of EGFR and are significantly different to control.
Notes: *Difference to control or free polymers (gray bars) within each group separated by indicator lines; #significant difference of each formulation containing ASOND or 
DOX compared to free DOX or AsOND (P , 0.05); data are mean sD (n = 3).
Abbreviations: AsOND, antisense oligonucleotide; DOX, doxorubicin; egFr, epidermal growth factor receptor; NAc-c, N-acetyl cysteine-chitosan; NAP-c, N-acetyl 
penicillamine-chitosan; LMWc, low-molecular-weight chitosan; rPMI, roswell Park Memorial Institute medium; FBs, fetal bovine serum; PBs, phosphate buffered saline; sD, 
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Figure 7 Analysis of egFr protein expression in T47D cells. (A)  Western blot analysis of egFr expression in T47D cells through different treatments;  (B) immunocytochemical 
analysis of egFr protein expression in T47D cells. (1) FBs-free rPMI; (2) AsOND; (3) DOX; (4) NAc-c; (5) AsOND + NAc-c; (6) DOX + NAc-c;, (7) NAP-c; (8) 
AsOND + NAP-c; (9) DOX + NAP-c; (10) chitosan; (11) AsOND + chitosan; (12) DOX + chitosan. The brown stain signifies higher expression of this protein which is 
observed in cytoplasm and on the membrane of the cells and the blue stain indicates the nuclei of the cell.
Note: *Significantly different from FBs-free rPMI treated cells as controls (mean ± sD; n = 3).
Abbreviations: AsOND, antisense oligonucleotide; DOX, doxorubicin; egFr, epidermal growth factor receptor; NAc-c, N-acetyl cysteine-chitosan; NAP-c, N-acetyl 
penicillamine-chitosan; LMWc, low-molecular-weight chitosan; rPMI, roswell Park Memorial Institute medium; FBs, fetal bovine serum; PBs, phosphate buffered saline; sD, 
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DOX and DOX-containing nanoparticles decreased 
EGFR expression significantly (Figure 6 [3, 6, 9, 12])   
compared with control particles (Figure 6 [1, 4, 7, 10]). DOX 
decreased EGFR expression more than ASOND. Probably 
this   observation is due to DOX cytotoxic effects on T47D 
cells. In particular it was observed from cell survival data 
and EGFR expression level that thiolated chitosan poly-
mers cannot decrease the cell toxicity of this compound.   
It is clear that because of the high level of cytotoxicity 
observed with this compound and the mechanism of action, 
DOX is not the preferred drug in EGFR suppression studies 
causing high levels of cell death.
ASOND (Figure 6 [2]) decreased the expression of 
EGFR twice as much as control, while thiolated nanopar-
ticles containing ASOND (Figure 6 [5, 8, 11]) were twice 
as effective than ASOND or ASOND + LMWC (Figure 6 
[11]) nanoparticles in EGFR knock down. From drug 
release, cell survival, and gene expression data it could be 
concluded that thiolated chitosan nanoparticles containing 
ASOND decreased the cytotoxic effects of this compound 
probably due to a slower rate of release, resulting in higher 
levels of EGFR gene suppression. EGFR expression level 
was confirmed by gel electrophoresis on the end product of 
RT QPCR (data not shown).
Analysis of egFr protein expression  
in T47D cells
EGFR expression in T47D cells after different treatments 
was studied using Western blot analysis and cell antibody 
staining. Western blot and immunocytochemical results 
showed a significant downregulation of this protein in all 
treated groups except those treated with FBS-free RPMI, 
NAC-C, NAP-C, and chitosan (Figure 7A and B). The 
results show that ASOND-loaded particles (Figure 7A [5, 
8, 11]) downregulated EGFR expression approximately 
twice as much as free ASOND (Figure 7A [2]). DOX-
loaded nanoparticles (Figure 7A [6, 9, 12]) showed a similar 
result to free DOX (Figure 7A [3]). Thus EGFR protein 
expression data further confirm EGFR gene expression 
data obtained through different treatments. Cell staining 
using EGFR antibody was performed. The control cells 
and cells treated with empty particles showed expression 
of EGFR protein in cytoplasmic portion and the membrane 
of the cells (Figure 7B [1, 4, 7, 10]). The intensity of the 
stain decreased through treatment with either free DOX or 
ASOND (Figure 7B [2, 5]) and the expression was very low 
when nanoparticles loaded with DOX and ASOND were 
incorporated (Figure 7B [3, 6, 8, 9, 11]). Normally EGFR 
protein present on the cell membrane is internalized after 
activation of this protein which signifies the binding of this 
receptor to its substrate and activation of EGFR.29 While in 
T47D cells EGFR was observed in cytoplasmic and mem-
brane portion of the cells, the localization of this protein 
after treatment was mostly on the cell membrane, which 
could signify a lower degree of expression due to either 
EGFR knock down by ASOND or inhibition of production, 
leading to lower functionality of this protein shown by a 
lower internalization level.
Conclusion
In this study the anticancer drugs ASOND and DOX were 
loaded into two recently synthesized thiolated chitosan 
polymers, NAC-C and NAP-C, by a gelation method. The 
efficiency of nanoparticle formulations against EGFR expres-
sion was evaluated in vitro on T47D breast cancer cells, with 
promising results.
The particle size and morphology of polymer nanopar-
ticles depend on the structure and molecular weight of poly-
mer, pH and ionic strength of the surrounding environment, 
method of preparation, and the charge of the polymer used 
for nanoparticle formulation. Thiolated chitosan under opti-
mum conditions physically condenses nucleic acids.30 This 
contributes to the formation of nanoparticles (200 ± 30 nm), 
with an acceptable level of cellular uptake demonstrated by 
downregulation of EGFR expression in T47D cells.
Different groups have investigated the potential benefits of 
ASOND-loaded chitosan nanoparticles in different settings. 
Ozbas-Turan et al have shown the potential of chitosan as a 
carrier of ASOND across the skin barrier to inhibit β-Gal with 
a long and sustained effect. The high permeability of ASOND 
into skin layer was noted to be probably due to the effect of 
chitosan on tight junctions and an increase in permeability.31 
Manchanda et al have described that controlled-size chitosan 
nanoparticles produced using reverse micellar system is an 
efficient biocompatible ASOND delivery system with high 
cellular viability compared with lipofectamine.32 It has also 
been shown that chitosan nanoparticles protect the ASOND 
molecule during preparation and treatment.33 Protection of 
DNA from enzymatic degradation through these nanopar-
ticles, which is critical for in vivo efficiency and a highly tar-
geted delivery, is another known beneficial effect observed.34 
Despited all the positive and promising results published, the 
use of these particles in in vivo studies is still limited. Thus, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1974
Talaei et al
more in vitro studies are needed to further evaluate the poten-
tial use of such particles systematically in vivo.
The presence of thiol groups on the surface of the thio-
lated chitosan polymers (NAC-C and NAP-C) confers high 
mucoadhesive properties to the polymer, and the covalent 
cross linkage between sulfhydryl groups present on thiolated 
chitosan contributes to the formation of uniform nanopar-
ticles stable in both acidic and basic media, as previously 
shown by our group.14
Recently Gazori et al investigated the significant inhibitory 
effect of ASOND-loaded chitosan/alginate nanoparticles on 
EGFR expression in T47D cells,35 which show the ASOND 
protective properties of chitosan polymer while creating a 
sustained release delivery system for ASOND and DOX. 
Here we show that the use of thiolated chitosan also prevents 
the degradation of the active substances promoting sustained 
release properties. According to the results obtained from 
our loading/release studies and resistance to acidic and basic 
media, NAC-C and NAP-C particles are able to protect and 
release the active substances within a set period of time, leading 
to a significant decrease in the expression level of EGFR.
In comparison with chitosan, thiolated chitosan nanopar-
ticles gain triggered release properties in reducing environments 
and have a higher degree of structural stability and mucoadhe-
siveness. These particles have an acceptable drug-loading/cap-
ture capacity and show a significantly higher rate of transfection, 
as observed by the high level of EGFR knock down through 
ASOND therapy. Thus, ASOND-loaded NAC-C and NAP-C 
nanoparticles seem to be good candidates for a more in-depth 
cancer therapy research in future experiments in vivo.
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